Integrating Structural Insights, Orthogonal Biophysics, & AI to Accelerate Discovery of Novel Targets & De-Risk Candidate Development Across Europe
The Rational Drug Design Europe Summit is the dedicated forum bringing together structural biologists, biophysicists, medicinal chemists, drug discovery scientists, computational chemists, and AI drug discovery leaders committed to transforming the future of drug development.
As biopharma organizations face increasing pressure to identify high-value targets, reduce attrition rates and accelerate timelines to the clinic, rational drug design has become a cornerstone of modern discovery strategies. By leveraging deep insights into molecular interactions and protein structure, researchers can make more informed decisions earlier in the discovery process, improving efficiency and increasing confidence in candidate selection.
Advances in structural biology, orthogonal biophysics, and AI are enabling researchers to better understand disease mechanisms, identify druggable targets, validate molecular interactions, and design molecules with greater precision. Together, these technologies are accelerating drug discovery, improving decision-making, and reducing development risk.
Despite growing innovation across the field, Europe has lacked a dedicated meeting focused on the intersection of rational drug design, structural biology, biophysics and AI-enabled drug discovery. The Rational Drug Design Europe Summit has been established to unite experts across disciplines, facilitate knowledge exchange and advance next-generation drug discovery strategies.
Partner with the Rational Drug Design Summit Europe
As innovation continues across structural biology, biophysics and AI-enabled drug discovery, the Rational Drug Design Summit Europe offers service and solution providers a focused platform to engage decision-makers and scientific leaders driving the future of pharmaceutical research.
Attending Companies Include